Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19

Am J Trop Med Hyg. 2020 Jun;102(6):1154-1155. doi: 10.4269/ajtmh.20-0262.

Authors

Catherine E Oldenburg^{1

2

3}, Thuy Doan^{2

1}

Affiliations

¹ Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
² Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.

No abstract available

Publication types

Editorial

MeSH terms

Antiviral Agents / therapeutic use*
Azithromycin / therapeutic use
Betacoronavirus / drug effects
Betacoronavirus / pathogenicity*
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques / standards
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Drug Repositioning
Humans
Hydroxychloroquine / therapeutic use
Lopinavir / therapeutic use
Pandemics*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Practice Guidelines as Topic
Randomized Controlled Trials as Topic / standards*
Ritonavir / therapeutic use
SARS-CoV-2
Sample Size
United States / epidemiology

Substances

Antiviral Agents
Lopinavir
Hydroxychloroquine
Azithromycin
Ritonavir